A61K 9/5078
With drug-free core
Official title: {with drug-free core}
A61K9/5078 (With drug-free core) appears on 1,248 US grants and 1,896 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,248
- Published applications
- 1,896
- Assignees
- 683
- Inventors
- 2,694
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 4 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 4 | 0 |
| 1982 | 3 | 0 |
| 1983 | 2 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 8 | 0 |
| 1988 | 7 | 0 |
| 1989 | 21 | 0 |
| 1990 | 17 | 0 |
| 1991 | 12 | 0 |
| 1992 | 11 | 0 |
| 1993 | 19 | 0 |
| 1994 | 20 | 0 |
| 1995 | 19 | 0 |
| 1996 | 13 | 0 |
| 1997 | 29 | 0 |
| 1998 | 22 | 0 |
| 1999 | 27 | 0 |
| 2000 | 31 | 0 |
| 2001 | 32 | 10 |
| 2002 | 22 | 37 |
| 2003 | 38 | 67 |
| 2004 | 19 | 73 |
| 2005 | 10 | 56 |
| 2006 | 17 | 67 |
| 2007 | 11 | 72 |
| 2008 | 13 | 95 |
| 2009 | 11 | 93 |
| 2010 | 36 | 101 |
| 2011 | 21 | 109 |
| 2012 | 33 | 74 |
| 2013 | 38 | 88 |
| 2014 | 75 | 86 |
| 2015 | 45 | 124 |
| 2016 | 71 | 131 |
| 2017 | 68 | 100 |
| 2018 | 69 | 74 |
| 2019 | 53 | 75 |
| 2020 | 57 | 67 |
| 2021 | 61 | 69 |
| 2022 | 33 | 59 |
| 2023 | 36 | 41 |
| 2024 | 45 | 60 |
| 2025 | 33 | 40 |
| 2026 | 16 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Prolonged-release pharmaceutical composition for oral administration of sultiame6 Oct 2026US 12,751,928 B2Advicenne
- Pharmaceutical composition comprising meloxicam22 Sep 2026US 12,740,988 B2Mylan Laboratories Limited
- Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics8 Sep 2026US 12,728,110 B2Flamel Ireland Limited
- Delayed-release formulation of duloxetine1 Sep 2026US 12,721,817 B1Almatica Pharma LLC
- Preparation of solid dosage forms comprising antibodies by solutions/suspension layering16 Jun 2026US 12,653,786 B2Tillotts Pharma AG
- Pharmaceutical formulations comprising naltrexone and/or bupropion13 Aug 2026US 2026/0232599 A1Nalpropion Pharmaceuticals LLC
- Pellet of dabigatran etexilate or pharmaceutically acceptable salt thereof6 Aug 2026US 2026/0224545 A1Bostal Drug Delivery Co., Ltd.
- Metformin hydrochloride enteric-coated preparation30 Jul 2026US 2026/0216081 A1Yayan (Tianjin) Biomedical Technology Center (Limited Partnership)
- Taste Masking Composition and Process23 Jul 2026US 2026/0207515 A1Tulex Pharmaceuticals Inc.
- Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof23 Jul 2026US 2026/0207534 A1Ensysce Biosciences Inc.
Most cited
By later US patents
- Particle immobilized coatings and uses thereof1,386US 8,679,454 B2SurModics, Inc. · 2014
- Controlled release formulations coated with aqueous dispersions of acrylic polymers1,011US 5,639,476 AEuro-Celtique S. A. · 1997
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003